Oral LYT-100 (deupirfenidone) was found to be safe and well-tolerated at all doses in an ongoing Phase 1 trial evaluating its potential to treat disorders involving inflammation and fibrosis, such as idiopathic pulmonary fibrosis (IPF), and disorders of lymphatic flow. “Based on these results, we plan to move…
Potential IPF Treatment, LYT-100, Shows Good Tolerability in Trial
The Three Lakes Foundation, a nonprofit supporting better ways of diagnosing and treating pulmonary fibrosis (PF), announced the release of “Second Wind,” a short documentary film highlighting the need for organ donation. The documentary tells the story of Nick Brown of Indiana and his years of struggle until…
The first patient has enrolled in a clinical trial to understand the effect of Ofev (nindetanib) on adults who developed pulmonary fibrosis (PF) following acute lung injury from COVID-19 infection. “A significant percentage of COVID-19 patients with acute lung injury may develop lung fibrosis based on clinical…
Five years ago, every change in my health status or that of a loved one had the potential to become a catastrophe in my mind. Learning that a loved one was unwell used to send me into a weeks-long obsessive panic. I would get freaked out by what…
The Pulmonary Fibrosis Foundation (PFF), which supports research that advance understanding and better ways of treating pulmonary fibrosis (PF), is calling for submissions for next year’s PFF Scholars program for emerging scientists. Program winners will receive up to $50,000 over two years for PF research that may ultimately lead…
Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and patient registry. They shared about how their respective organizations came to be, as well as the benefits of creating patient registries and how they can help…
The words “palliative care” often frighten those of us living with a life-threatening illness. This is because the term historically has been associated with end-of-life care due to its link with hospice care. But the two terms were formally separated in 1990, when the World Health Organization officially recognized palliative…
A first patient has been enrolled in a proof-of-concept Phase 2 trial of C21 (VP01), Vicore Pharma’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF) and other lung diseases. “We are pleased to announce that we can now start our IPF trial despite the ongoing COVID-19…
The Pulmonary Fibrosis Foundation (PFF) plans to launch “Pinpoint PF,” an educational and awareness campaign for those at risk of pulmonary fibrosis (PF) or showing symptoms, in December. “We introduced the campaign … during the PFF’s virtual Volunteer Meeting and received an enthusiastic response from our PFF Ambassadors…
Newly developed therapies may hold promise for the treatment of pulmonary fibrosis, as described in two studies. The therapies, which are expected to move into clinical trials in the next several months, were both developed by Purdue University scientists in Indiana, led by Philip…
